Nov 13, 2007 by Brian Orelli, PhDMerck: Case Closed?Now that Merck has settled its lawsuit, it can get back to business.
Nov 13, 2007 by Brian Orelli, PhDAnother Punch in the Nose for PfizerThe FDA clears ZYRTEC-D for over-the-counter sales.
Nov 12, 2007 by Brian Orelli, PhDRaising the BarrBarr's acquisition increases sales, but it can't raise the bottom line.
Nov 12, 2007 by Brian Orelli, PhDValuing a BreakupAbraxis makes its final earnings report before it becomes two companies.
Nov 9, 2007 by Brian Orelli, PhDP&G Gives Nastech a Bloody NoseP&G ends its partnership to develop a nasal spray to treat osteoporosis.
Nov 8, 2007 by Brian Orelli, PhDThe 2 Sides of Bio-RadResults for the third quarter reflect stellar clinical sales combined with mediocre laboratory sales.
Nov 8, 2007 by Brian Orelli, PhDInvestors Prefer Black OnyxSales of Nexavar increase enough for Onyx to show a profit.
Nov 7, 2007 by Brian Orelli, PhDMomenta StoppedMomenta and Novartis receive a not-approvable letter for their ANDA.
Nov 6, 2007 by Brian Orelli, PhDGetting Vaccinated Alongside MomMerck presents data supporting use of its vaccine in older women.
Nov 6, 2007 by Brian Orelli, PhDOmrix Shifts to Stop the BleedingIncreased sales of biosurgery products partly compensate for a lost biodefense contract.
Nov 5, 2007 by Brian Orelli, PhDLast Look at Mini-MylanAn impending merger should more than double revenue.
Nov 5, 2007 by Brian Orelli, PhDCan't Beat BD's Steady GrowthHigher revenue and lower expenses make for a good quarter.
Nov 1, 2007 by Brian Orelli, PhDMore Extrinsic Growth From Inverness on the WayTrading stock for revenues is becoming second nature for Inverness.
Nov 1, 2007 by Brian Orelli, PhDGood News From Amylin Isn't Good EnoughInvestors aren't impressed by Amylin's extended-release version of Byetta.
Oct 31, 2007 by Brian Orelli, PhDFrom Apples to Apple Pie at TevaThe year-over-year comparison is rough, but the company still produces decent growth.
Oct 31, 2007 by Brian Orelli, PhDA Slimmer SepracorIt has reduced its sales team after government price cuts for one of its top drugs.
Oct 30, 2007 by Brian Orelli, PhDLaurels, Shmaurels, Let's GrowSonoSite produces another impressive quarter.
Oct 29, 2007 by Brian Orelli, PhDFoolish Forecast: Tenacious TevaViews you can use to get clues on tomorrow's news.
Oct 29, 2007 by Brian Orelli, PhDThe Extended Release That Wasn'tThe FDA is investigating Teva's generic version of Wellbutrin XL.
